.webp){kind=logo}
Direct-to-Consumer, Direct-to-Risk? How to Avoid Privacy Pitfalls in Pharma and Med Device Marketing
Direct-to-consumer marketing is quickly becoming a core growth channel for medical device, pharma, and life sciences brands. But with this opportunity comes escalating privacy and compliance risks that can no longer be ignored.
In this article, you’ll learn why traditional tracking tools like Meta Pixel and Google Analytics are triggering costly lawsuits, how evolving regulations and platform policies are reshaping the landscape, and what a privacy-first marketing approach looks like, so you can grow your DTC efforts without jeopardizing patient trust or running afoul of the law.
The Rise of Direct-to-Consumer Marketing
Medical device and pharma teams are doubling down on direct-to-consumer (DTC) marketing, and the investment shows. In 2022, the pharmaceutical industry spent approximately $7.6 billion on DTC advertising in the U.S—an annual increase of almost six percent.
From sleep apnea and diabetes to fertility and weight loss, DTC campaigns are:
- Driving traffic directly to branded websites
- Encouraging patients to request devices or therapies by name
- Promoting virtual consultations, find a doctor pages, and lead-gen flows
This patient-first pivot opens up enormous opportunities, but also invites serious risk if not done with a privacy-first mindset.
Recent Lawsuits Sound the Alarm
Several high-profile class-action lawsuits are making it clear: digital marketing practices are now legal minefields, especially when tracking tools like Meta Pixel and Google Analytics are involved.
GoodRx: Privacy Litigation & FTC Enforcement
Allegation: GoodRx shared users’ health data, including prescription searches and conditions, with third-party advertisers like Facebook and Google via tracking technologies.
The outcome: In 2023, GoodRx settled with the FTC for $1.5 million and agreed to stop sharing health data for ad purposes. In 2024, it agreed to a $25 million class action settlement without admitting wrongdoing.
Amgen: Co-pay Program Tracking Lawsuit
Allegation: Amgen allegedly embedded tracking pixels on its co-pay assistance site, sharing patients’ personal and health-related enrollment data, including diagnoses and prescriptions, with Meta and Google.
The outcome: In 2024, most claims were dismissed by the court, including statutory privacy and consumer protection claims. However, a claim for invasion of privacy survived, and the case continues on the limited privacy tort theory.
These lawsuits aren’t just cautionary tales for the life science industry. They signal a major shift: even traditionally B2B sectors like medical devices are now under the same privacy microscope as pharma and DTC health brands.
If you’re running lead-gen campaigns for regulated health products, whether it’s medical devices like insulin pumps, sleep apnea monitors, or at-home fertility tools, or even pharmaceutical therapies via direct-to-consumer channels, your digital footprint is under the microscope. The same tracking tools that help you reach the right audience and measure campaign performance can also expose your organization to legal risk. This isn’t hypothetical. It’s already happening.
Not Just Lawsuits: Platform Shifts and Patient Trust Are on the Line
Legal risk is just one piece of the puzzle. Digital platforms and regulators are also cracking down, and patients are paying attention.
- Meta and Google are tightening healthcare ad policies. Meta has already limited targeting options for health-related ads, and both platforms are scrutinizing data use more aggressively. Violations can mean ad account suspensions, reduced reach, or banned campaigns.
- Regulators are updating their playbooks. State-level laws like Washington’s My Health My Data Act go far beyond HIPAA, and signal a future where consumer privacy is treated as a fundamental right, not just a compliance checkbox.
- Reputation and trust are fragile. Patients want transparency and control over how their data is used. Even the perception of shady tracking practices can damage brand equity and hurt engagement.
Bottom line: privacy-first marketing isn’t just about avoiding lawsuits. It’s about keeping your campaigns live, your patients engaged, and your brand ahead of the curve.
More Laws are Coming, and They're Stricter Than HIPAA
HIPAA wasn’t designed with digital advertising in mind, leaving a gap that state laws are now rushing to fill. Regulations like California’s CPRA and Washington’s My Health My Data Act are expanding the definition of sensitive health information to include things like IP addresses, browsing behavior, and other online activity.
In practical terms, this means that simply visiting a webpage about a medical device could be classified as a health-related action, and sharing that data through tracking pixels might actually break the law.
What This Means for DTC Marketers
Digital marketers in medical device, pharma, and life sciences companies are under pressure to launch high-performing campaigns, prove ROI, and generate leads or script starts—often by tapping into the same platforms driving results in other industries, like Meta and Google. The DTC shift is redefining how brands build awareness, drive conversions, and create demand outside of the traditional provider model. But without the right privacy controls in place, those same tactics can quickly backfire.
From state-level lawsuits and federal privacy violations to platform penalties and patient trust erosion, the risks are mounting. DTC marketers aren’t just navigating performance goals anymore—they’re operating in a new regulatory and reputational reality.
To succeed, it’s not enough to drive results, you have to do it in a way that’s provably privacy-first.
The Path Forward: Compliant DTC Marketing is Possible
Staying compliant doesn’t mean sacrificing results, and some of the most forward-thinking healthcare brands are proving it.
CASE STUDY: A Global Med Device Brand Rebuilds Post-Pixel
When the diabetes division of a major medical device company was forced to remove the Meta Pixel for compliance reasons, the fallout was immediate. Leads dropped by 90%, and cost-per-lead skyrocketed from $500 to over $5,000. But rather than retreat from DTC, the team reimagined their approach.
They partnered with Freshpaint to implement HIPAA-compliant tracking, restored lost leads on Meta, and uncovered new lead-gen opportunities on TikTok. That success paved the way for expansion across other global domains, and now, they’re scaling across LinkedIn, Google Ads, Bing, and Reddit with confidence.
The takeaway? Privacy-first doesn’t mean performance-last. With the right tools and guardrails, it’s possible to protect patient data, preserve attribution, and keep legal, IT, and marketing aligned, all without losing momentum.
The Privacy-First Framework
So, how do you build a direct-to-consumer strategy that drives results and holds up to scrutiny? You need to build around a privacy-first framework. Here’s how leading healthcare marketers are making it happen.
1. Audit: Create a complete list of tracking tools on your site by collaborating with marketing, product, IT, and legal teams. Identify each tool, who owns it, and whether it collects PHI.
2. Analyze: Determine which tools collect PHI by checking what data they access—IP addresses + health info = privacy risk.
3. Verify: Check if you have a valid Business Associate Agreement (BAA) with each tool collecting PHI. If not, get one or replace the tool.
4. Govern: For tools without BAAs, either build a solution to block PHI or use a Healthcare Privacy Platform (like Freshpaint) to control data flow.
5. Monitor: Track new tools monthly with your IT team. If something new pops up, loop back to Step 2.
.jpg)
This framework isn’t just a checklist. It’s how leading DTC marketers turn privacy risk into a competitive advantage.
Growing DTC = Growing Privacy Stakes
The push toward direct-to-consumer marketing is accelerating, but so is the legal scrutiny.
Lawsuits like those against GoodRX and Amgen are just the beginning. With regulators, platforms, and class-action lawyers watching closely, it’s no longer enough to be “HIPAA-aligned.”
You need to be proactively, measurably compliant. That’s where Freshpaint comes in to help healthcare marketers:
- Run performance-focused DTC campaigns
- Stay compliant with HIPAA and state privacy laws
- Keep legal, IT, and marketing aligned and moving fast
